Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | NSD2 | O96028 | 1/20 | 0.48 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13881832 | 0.88 | L3MBTL1 (0.46) | L3MBTL1KDM4ESMN1; SMN2ALDH1A1LTB4R | |
| SCHEMBL29818782 | 0.87 | L3MBTL1 (0.50) | L3MBTL1KDM4ESMN1; SMN2ALDH1A1LTB4R | |
| SCHEMBL2207783 | 0.87 | L3MBTL1 (0.50) | L3MBTL1KDM4ESMN1; SMN2ALDH1A1LTB4R | |
| SCHEMBL25823443 | 0.87 | CACNA1B (0.48) | KDM4ESMN1; SMN2ALDH1A1NSD2LMNA | |
| SCHEMBL4569128 | 0.86 | L3MBTL1 (0.45) | L3MBTL1KDM4ESMN1; SMN2ALDH1A1LTB4R | |
| SCHEMBL4568895 | 0.86 | L3MBTL1 (0.52) | L3MBTL1SMN1; SMN2ALDH1A1LTB4RLMNA | |
| SCHEMBL13881830 | 0.86 | L3MBTL1 (0.44) | L3MBTL1SMN1; SMN2LTB4R | |
| SCHEMBL19291502 | 0.86 | L3MBTL1 (0.44) | L3MBTL1KDM4ESMN1; SMN2ALDH1A1LTB4R | |
| SCHEMBL15151081 | 0.83 | CA1 (0.45) | L3MBTL1LTB4R | |
| SCHEMBL25818192 | 0.82 | KDM4E (0.46) | KDM4ESMN1; SMN2ALDH1A1NSD2AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | L3MBTL1 2438/4885KDM4E 2227/4885SMN1; SMN2 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.